




Annex to the Press Release

Evolution diagnostic trade sales (in thousands EUR)



HPV: Human papillomaviruses are a group of over 100 types of viruses of which 30 are sexually transmissible. Specific high-risk HPVs are the major cause of cervical cancer, the second most common cancer in women.

HLA: Human leukocyte antigen: a set of proteins expressed on the surface of cells that allow the body to discriminate between self and non-self. Before transplantation, the process of tissue typing determines the presence and absence of these proteins to ensure that the organ donor and recipient are compatible.

LiPA or line probe assay is a DNA-based, multiparameter (ie, able to measure many items with one test) detection and identification technology that provides high value-added diagnostic information to physicians throughout therapy, enabling them to optimize the therapeutic regimen of patients.

LIA[®] or line immunoassay tests are advanced confirmatory tests allowing rapid and simultaneous detection and differentiation of multiple disease parameters, such as antibodies, in human serum or plasma samples.



INNOGENETICS[®]
BIOTECHNOLOGY FOR HEALTHCARE

Unaudited Consolidated Income Statement

All information in thousands EUR, except share amounts
According to IFRS

	3 months ended	
	March 2008	March 2007
Product sales	13.269	12.255
Royalties	1.000	975
<u>License fees</u>	<u>989</u>	<u>11</u>
Revenues	15.258	13.241
<u>Cost of sales</u>	<u>(6.127)</u>	<u>(6.014)</u>
Gross profit/(loss)	9.131	7.227
Grants received for R&D	174	429
R&D contract income	598	575
<u>R&D expenses</u>	<u>(5.024)</u>	<u>(7.095)</u>
Research and development	(4.252)	(6.091)
Marketing & sales expenses	(3.628)	(4.052)
<u>Administration expenses</u>	<u>(2.608)</u>	<u>(953)</u>
Operating expenses	(6.236)	(5.005)
Operating profit/(loss) before restructuring & impairment losses	(1.357)	(3.869)
Restructuring & impairment losses	(11.364)	-
Operating profit/(loss) (EBIT)	(12.721)	(3.869)
Interest expenses	(851)	(469)
Interest income	221	131
<u>Investment income and other</u>	<u>5.155</u>	<u>230</u>
Other income/(expenses)	4.525	(108)
Profit/(loss) before taxes	(8.196)	(3.977)
Income taxes – (payable)/adjustment	(139)	(33)
Net profit/(loss)	<u>(8.335)</u>	<u>(4.010)</u>
Operating profit/(loss) before depreciation and amortization (EBITDA)	(3.000)	(1.629)
EPS from continuing operations (basic/diluted)	(0.27)	(0.13)
Shares used in computing per share amount (basic/diluted)	30.878.920	30.878.920



INNOGENETICS[®]
BIOTECHNOLOGY FOR HEALTHCARE

Unaudited Consolidated Balance Sheet

	March 2008	December 2007
ASSETS		
Current assets		
Cash and cash equivalents	13.160	23.478
Accounts receivable	18.050	19.060
Inventories	10.938	10.210
<u>Other accounts receivable</u>	<u>7.632</u>	<u>1.621</u>
Total current assets	49.780	54.369
Non-current assets		
Intangible assets	22.862	30.597
Property, plant and equipment	18.646	19.600
<u>Accounts receivable more than one year</u>	<u>358</u>	<u>359</u>
Total non-current assets	41.866	50.556
TOTAL ASSETS	91.646	104.925
LIABILITIES & SHAREHOLDERS' EQUITY		
Current liabilities		
Current instalments of long-term obligations	8.478	9.932
Trade accounts payable	7.541	8.798
Other current liabilities	13.895	14.579
<u>Current tax liabilities</u>	<u>226</u>	<u>187</u>
Total current liabilities	30.140	33.496
Non-current liabilities		
Long-term obligations	36.297	41.039
Provisions	4.590	762
<u>Other non-current liabilities</u>	<u>1.270</u>	<u>1.677</u>
Total non-current liabilities	42.157	43.478
Shareholders' equity		
Share capital	19.398	19.398
Issuance premium	163.089	163.070
Reserves	(1.787)	(1.501)
<u>Retained earnings</u>	<u>(161.351)</u>	<u>(153.016)</u>
Total shareholders' equity	19.349	27.951
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	91.646	104.925



INNOGENETICS[®]
BIOTECHNOLOGY FOR HEALTHCARE

Unaudited Consolidated Statement of Shareholders' Equity

Movements during the three months of 2007

	Equity attributable to the equity holders of the Company					
	Number of shares issued	Share capital	Issuance premium	Retained earnings	Accumulated currency translation and fair value adjustments	TOTAL shareholders' equity
Total as per December 31, 2006	30.878.920	19.398	157.419	(135.639)	(856)	40.322
Currency translation adjustment	-	-	-	-	(44)	(44)
Net profit/(loss)	-	-	-	(4.010)	-	(4.010)
Recognition of share-based payment	-	-	83	-	-	83
Recognition of equity component of convertible bond	-	-	5.521	-	-	5.521
Total as per March 31, 2007	30.878.920	19.398	163.023	(139.649)	(900)	41.872

Movements during the three months of 2008

Total as per December 31, 2007	30.878.920	19.398	163.070	(153.016)	(1.501)	27.951
Currency translation adjustment	-	-	-	-	(286)	(286)
Net profit/(loss)	-	-	-	(8.335)	-	(8.335)
Recognition of share-based payment	-	-	19	-	-	19
Total as per March 31, 2008	30.878.920	19.398	163.089	(161.351)	(1.787)	19.349



INNOGENETICS[®]
BIOTECHNOLOGY FOR HEALTHCARE

Unaudited Consolidated Statement of Cash Flows

	3 months ended	
	March 2008	March 2007
CASH FLOWS FROM OPERATING ACTIVITIES		
Net Profit/(loss)	(8.335)	(4.010)
Depreciation, amortization and impairment results	9.721	2.240
Increase/(decrease) in provisions	3.828	(1.929)
Share-based payment	19	84
Gain on disposal of fixed assets	(40)	(37)
Loss on disposal of fixed assets	43	30
Interest paid	851	479
Interest received	(210)	(131)
(Increase)/decrease in accounts receivable	(5.003)	378
(Increase)/decrease in inventories	(728)	(481)
(Increase)/decrease in current tax assets	-	(22)
Increase/(decrease) in accounts payable	(1.257)	(465)
Increase/(decrease) in accruals and other liabilities	(1.325)	(677)
Increase/(decrease) in current tax liabilities	39	(85)
Increase/(decrease) in non-current liabilities	(405)	(183)
Total adjustments	5.533	(799)
Net cash used in operating activities	(2.802)	(4.809)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(734)	(808)
Purchase of intangible assets	(302)	(1.099)
Net cash used in investing activities	(1.036)	(1.907)



INNOGENETICS[®]
BIOTECHNOLOGY FOR HEALTHCARE

**Unaudited Consolidated Statement of Cash Flows
(Continued)**

	3 months ended	
	March 2008	March 2007
CASH FLOWS FROM FINANCING ACTIVITIES		
Payments on long-term obligations	(6.622)	(922)
Proceeds from long-term obligations	427	762
Payments on notes payable to bank	-	(913)
Proceeds from notes payable to bank	-	199
Currency translation adjustment	(285)	(44)
Proceeds from issuance of convertible bond	-	30.664
<hr/>		
Net cash provided by/(used in) financing activities	(6.480)	29.746
<hr/>		
Net increase/(decrease) in cash and cash equivalents	(10.318)	23.030
Cash and cash equivalents at beginning of year	23.478	22.349
Cash and cash equivalents at end of period	13.160	45.379



INNOGENETICS
BIOTECHNOLOGY FOR HEALTHCARE

Unaudited Segment Information

	Diagnostics		Therapeutics		Total	
	3 months ended March 2008	3 months ended March 2007	3 months ended March 2008	3 months ended March 2007	3 months ended March 2008	3 months ended March 2007
Revenues	14.171	12.338	1.087	903	15.258	13.241
Gross profit	8.883	7.153	248	74	9.131	7.227
Research & Development income	148	325	624	679	772	1.004
<u>Research & Development expenses</u>	<u>(2.891)</u>	<u>(3.843)</u>	<u>(2.133)</u>	<u>(3.252)</u>	<u>(5.024)</u>	<u>(7.095)</u>
Research & Development	(2.743)	(3.518)	(1.509)	(2.573)	(4.252)	(6.091)
Operating expenses	(5.209)	(4.028)	(1.027)	(977)	(6.236)	(5.005)
Operating profit/(loss) before restructuring & impairment losses	931	(393)	(2.288)	(3.476)	(1.357)	(3.869)
Restructuring & impairment losses	(52)	-	(11.312)	-	(11.364)	-
Operating profit/(loss) before depreciation and amortization (EBITDA)	2.488	1.220	(5.488)	(2.849)	(3.000)	(1.629)
Operating profit/(loss) (EBIT)	879	(393)	(13.600)	(3.476)	(12.721)	(3.869)